CYP11B2
Cytochrome P450 11B2, mitochondrial
As of the edition of 20 October 2026, CYP11B2 (cytochrome P450 11B2, mitochondrial, UniProt P19099) has 5 drugs tested at it and 9 companies on the list, 1 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P19099
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 7
- Disease areas
- Heart and blood vessels; Hormones; Pregnancy and women's health; Urinary and reproductive; Nutrition and metabolism; Nervous system; Digestive system; Lungs and airways
- Registered trials of its drugs
- 61
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 2 |
| Went quiet | 1 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Baxdrostat | Marketed | Phase 3 | Ends 2033 |
| Vicadrostat | Active | Phase 3 | none listed |
| Levoketoconazole | Marketed | Phase 3 | Ends 2028 |
| Lorundrostat | Active | Phase 3 | none listed |
| LY3045697 | Went quiet | Phase 1 | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 2 |
| Engaged | 5 |
| Undetermined | 1 |
| Total on the list | 9 |
| Company | Route |
|---|---|
| AstraZeneca | Route B |
| Cortendo | Route B |
| Eli Lilly | Route A |
The other 6 companies at CYP11B2
In the product9 companies in all; 6 are not named here, and no score is.
See the 9 companies at CYP11B2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.